Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Dempfle, Carl Erik H ^a   Elmas, Elif ^a   Link, Andreas ^b   Suvajac, Nenad ^a   Liebe, Volker ^a   Janes, Jonathan ^c   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; D DIMER; DROTRECOGIN; ENOXAPARIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; PLACEBO; PLASMIN INHIBITOR; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPLORATORY RESEARCH; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; LUNG EMBOLISM; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BLOOD; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; METABOLISM; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PROTEIN C; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651382441     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9968     Document Type: Article

References (26)

1. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007, 5(Suppl 1):73-80. 10.1111/j.1538-7836.2007.02491.x, 17635713.
2. Jakubowski HV, Kline MD, Owen WG. The effect of bovine thrombomodulin on the specificity of bovine thrombin. J Biol Chem 1986, 261:3876-3882.
3. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007, 109:3161-3172. 10.1182/blood-2006-09-003004, 17110453.
4. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993, 92:2003-2012. 10.1172/JCI116795, 288368, 8408654.
5. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987, 79:918-925. 10.1172/JCI112902, 424237, 3102560.
6. Lyseng-Williamson KA, Perry CM. Drotrecogin alfa (activated). Drugs 2002, 62:617-630. discussion 631-612, 10.2165/00003495-200262040-00006, 11893230.
7. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925-929. 10.1056/NEJM198610093151503, 3531851.
8. Halvorsen S, Skjonsberg OH, Godal HC. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation. Blood Coagul Fibrinolysis 1993, 4:133-137.
9. Lijnen HR, Van Hoef B, De Cock F, Collen D. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA. Thromb Haemost 1990, 64:61-68.
10. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006, 26:2445-2453. 10.1161/01.ATV.0000244680.14653.9a, 16960106.
11. de Fouw NJ, de Jong YF, Haverkate F, Bertina RM. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S. Thromb Haemost 1988, 60:328-333.
12. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, Kinasewitz GT. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003, 90:642-653.
13. Vieillard-Baron A, Page B, Augarde R, Prin S, Qanadli S, Beauchet A, Dubourg O, Jardin F. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med 2001, 27:1481-1486. 10.1007/s001340101032, 11685341.
14. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992, 79:2340-2348.
15. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001, 29:S69-74. 10.1097/00003246-200107001-00024, 11445737.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
17. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933. 10.1111/j.1538-7836.2004.00955.x, 15550023.
18. Petaja J, Fernandez JA, Gruber A, Griffin JH. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest 1997, 99:2655-2663. 10.1172/JCI119454, 508111, 9169495.
19. Suzuki A, Ebinuma H, Matsuo M, Miyazaki O, Yago H. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res 2007, 121:377-385. 10.1016/j.thromres.2007.05.008, 17561232.
20. Matsuda M, Terukina S, Yamazumi K, Maekawa H, Soe G. A monoclonal antibody that recognizes the NH2-terminal conformation of fragment D. Fibrinogen 4: current Basic and Clinical Aspects 1990, 892:43-48. Amsterdam: Excerpta Medica, Matsuda M, Iwanaga S, Takada A, Henshen A.
21. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC, drotrecogin alfa activated) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003, 102:2093-2098. 10.1182/blood-2003-02-0416, 12750166.
22. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004, 21:222-229. 10.1097/01.shk.0000116778.27924.79, 14770034.
23. Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999, 100:2485-2490.
24. Hollenstein UM, Pernerstorfer T, Homoncik M, Hansen JB, Finzen H, Handler S, Jilma B. Effect of factor x inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis 2002, 186:1270-1276. 10.1086/344646, 12402196.
25. Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982, 704:461-469. 10.1016/0167-4838(82)90068-1, 6214279.
26. Mosesson MW, Siebenlist KR, Voskuilen M, Nieuwenhuizen W. Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost 1998, 79:796-801.